ERK1/2 activation mediated by the nutlin-3-induced mitochondrial translocation of p53

International Journal of Oncology

Volumn 42, Issue 3, 2013, Pages 1027-1035

  Lee, Sun Young ^a   Shin, Seok Joon ^a   Kim, Ho Shik ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Apoptosis; Extracellular signal regulated kinase 1 2; Mitogen activated protein kinase kinase 1 2; Murine double minute 2 protein; Tumor suppressor protein p53

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NUTLIN 3; PIFITHRIN ALPHA; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; VASCULOTROPIN RECEPTOR;

ARTICLE; ENZYME INACTIVATION; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

ANTIOXIDANTS; APOPTOSIS; BENZOTHIAZOLES; BUTADIENES; CELL LINE, TUMOR; CYCLIC N-OXIDES; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NITRILES; OSTEOSARCOMA; PHOSPHORYLATION; PIPERAZINES; PROTEIN TRANSPORT; QUINAZOLINES; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; TOLUENE; TUMOR SUPPRESSOR PROTEIN P53; TYRPHOSTINS;

EID: 84873679971     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1764     Document Type: Article

References (40)

1. Menendez D, Inga A and Resnick MA: The expanding universe of p53 targets. Nat Rev Cancer 9: 724-737, 2009.
2. Riley T, Sontag E, Chen P and Levine A: Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9: 402-412, 2008. (Pubitemid 351574202)
3. Honda R, Tanaka H and Yasuda H: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420: 25-27, 1997. (Pubitemid 28037193)
4. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW and Vogelstein B: Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 362: 857-860, 1993. (Pubitemid 23132165)
5. Reinhardt HC and Schumacher B: The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet 28: 128-136, 2012.
6. Sill H, Olipitz W, Zebisch A, Schulz E and Wölfler A: Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. Br J Pharmacol 162: 792-805, 2011.
7. Travis LB, Ng AK, Allan JM, et al: Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst 104: 357-370, 2012.
8. Shangary S and Wang S: Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 14: 5318-5324, 2008.
9. Dickens MP, Fitzgerald R and Fischer PM: Small-molecule inhibitors of MDM2 as new anticancer therapeutics. Semin Cancer Biol 20: 10-18, 2010.
10. Vassilev LT, Vu BT, Graves B, et al: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848, 2004. (Pubitemid 38174664)
11. Secchiero P, Bosco R, Celeghini C and Zauli G: Recent advances in the therapeutic perspectives of nutlin-3. Curr Pharm Des 17: 569-577, 2011.
12. Tovar C, Rosinski J, Filipovic Z, et al: Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 103: 1888-1893, 2006. (Pubitemid 43228788)
13. Mendrysa SM, O'Leary KA, McElwee MK, et al: Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev 20: 16-21, 2006. (Pubitemid 43042663)
14. Mebratu Y and Tesfaigzi Y: How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle 8: 1168-1175, 2009.
15. McCubrey JA, Steelman LS, Chappell WH, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007. (Pubitemid 47125967)
16. Persons DL, Yazlovitskaya EM and Pelling JC: Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem 275: 35778-35785, 2000.
17. Sablina AA, Chumakov PM, Levine AJ and Kopnin BP: p53 activation in response to microtubule disruption is mediated by integrin-Erk signaling. Oncogene 20: 899-909, 2001. (Pubitemid 32207107)
18. She QB, Bode AM, Ma WY, Chen NY and Dong Z: Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res 61: 1604-1610, 2001. (Pubitemid 34292594)
19. Lin T, Mak NK and Yang MS: MAPK regulate p53-dependent cell death induced by benzo[a]pyrene: involvement of p53 phosphorylation and acetylation. Toxicology 247: 145-153, 2008.
20. Lee SW, Fang L, Igarashi M, Ouchi T, Lu KP and Aaronson SA: Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53. Proc Natl Acad Sci USA 97: 8302-8305, 2000. (Pubitemid 30639667)
21. Fang L, Li G, Liu G, Lee SW and Aaronson SA: p53 induction of heparin-binding EGF-like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades. EMBO J 20: 1931-1939, 2001. (Pubitemid 32397395)
22. Ongusaha PP, Kim JI, Fang L, et al: p53 induction and activation of DDR1 kinase counteracts p53-mediated apoptosis and influence p53 regulation through a positive feedback loop. EMBO J 22: 1289-1301, 2003. (Pubitemid 36362693)
23. Yin Y, Liu YX, Jin YJ, Hall EJ and Barrett JC: PAC1 phosphatase is a transcription target of p53 in signaling apoptosis and growth suppression. Nature 422: 527-531, 2003. (Pubitemid 36433648)
24. Ueda K, Arakawa H and Nakamura Y: Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53. Oncogene 22: 5586-5591, 2003. (Pubitemid 37102694)
25. Li M, Zhou JY, Ge Y, Matherly LH and Wu GS: The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. J Biol Chem 278: 41059-41068, 2003. (Pubitemid 37280929)
26. Kojima K, Konopleva M, Samudio IJ, Ruvolo V and Andreeff M: Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells. Cancer Res 67: 3210-3219, 2007. (Pubitemid 46724859)
27. Zhang W, Konopleva M, Burks JK, et al: Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim. Cancer Res 70: 2424-2434, 2010.
28. Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108, 2008. (Pubitemid 351818697)
29. Jang JY, Kim MK, Jeon YK, et al: Adenovirus adenine nucleotide translocator-2 shRNA effectively induces apoptosis and enhances chemosensitivity by the down-regulation of ABCG2 in breast cancer stem-like cells. Exp Mol Med 44: 251-259, 2012.
30. Sauer L, Gitenay D, Vo C and Baron VT: Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Oncogene 29: 2628-2637, 2010.
31. McCubrey JA, Lahair MM and Franklin RA: Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid Redox Signal 8: 1775-1789, 2006. (Pubitemid 44726351)
32. Liu CM, Sun YZ, Sun JM, Ma JQ and Cheng C: Protective role of quercetin against lead-induced inflammatory response in rat kidney through the ROS-mediated MAPKs and NF-κB pathway. Biochim Biophys Acta 1820: 1693-1703, 2012.
33. Liu B, Chen Y and St Clair DK: ROS and p53: a versatile partnership. Free Radic Biol Med 44: 1529-1535, 2008.
34. Sansome C, Zaika A, Marchenko ND and Moll UM: Hypoxia death stimulus induces translocation of p53 protein to mitochondria. Detection by immunofluorescence on whole cells. FEBS Lett 488: 110-115, 2001. (Pubitemid 32103581)
35. Mihara M, Erster S, Zaika A, et al: p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11: 577-590, 2003. (Pubitemid 36385115)
36. Palacios G and Moll UM: Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo. Oncogene 25: 6133-6139, 2006. (Pubitemid 44562412)
37. Talos F, Petrenko O, Mena P and Moll UM: Mitochondrially targeted p53 has tumor suppressor activities in vivo. Cancer Res 65: 9971-9981, 2005. (Pubitemid 41541478)
38. Vaseva AV, Marchenko ND and Moll UM: The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells. Cell Cycle 8: 1711-1719, 2009.
39. Zhao Y, Chaiswing L, Velez JM, et al: p53 translocation to mitochondria precedes its nuclear translocation and targets mitochondrial oxidative defense protein-manganese superoxide dismutase. Cancer Res 65: 3745-3750, 2005. (Pubitemid 40616352)
40. Strom E, Sathe S, Komarov PG, et al: Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2: 474-479, 2006. (Pubitemid 44266309)